Skip to Content
Merck

32483

Voriconazole

VETRANAL®, analytical standard

Synonym(s):

2R,3S-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, UK-109496

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C16H14F3N5O
CAS Number:
137234-62-9
Molecular Weight:
349.31
NACRES:
NA.24
PubChem Substance ID:
329754241
UNSPSC Code:
41116107
MDL number:
MFCD00905717

Product Name

Voriconazole, VETRANAL®, analytical standard

InChI key

BCEHBSKCWLPMDN-MGPLVRAMSA-N

SMILES string

C[C@@H](c1ncncc1F)[C@](O)(Cn2cncn2)c3ccc(F)cc3F

InChI

1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1

grade

analytical standard

product line

VETRANAL®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

forensics and toxicology
pharmaceutical (small molecule)

format

neat

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Biochem/physiol Actions

It has been used as one of the constituent of YPD (1% yeast extract, 2% peptone, 2% glucose) liquid media.
Voriconazole is an antifungal used to treat serious fungal infections. Voriconazole inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-α sterol demethylase resulting in a depletion of ergosterol in fungal cell membranes.
Voriconazole is an antifungal used to treat serious fungal infections. Voriconazole inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-a sterol demethylase resulting in a depletion of ergosterol in fungal cell membranes.
Voriconazole is an antifungal, which inhibits ergosterol synthesis.

General description

Voriconazole is a second-generation triazole, and is derived from fluconazole. It has a broad and enhanced antifungal spectrum as compared to other older triazoles. It is mostly well tolerated and is available in both oral and intravenous formulations.

Legal Information

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Chronic 3 - Carc. 2 - Muta. 2 - Repr. 2 - STOT RE 1 - STOT RE 2 Oral - STOT SE 2 Oral

target_organs

Eyes, Liver,Kidney

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCM3810
BCCJ3748
BCCD1754
BCBZ8761
BCBS3721V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Convergent evolution of calcineurin pathway roles in thermotolerance and virulence in Candida glabrata.
Chen, Ying-Lien, et al.
G3 (Bethesda, Md.), 2 (6), 675- 691 (2012)
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht, Raoul, et al.
The New England Journal of Medicine, 347 (6), 408-415 (2002)
Voriconazole: a new triazole antifungal agent.
Saravolatz, Louis D., Leonard B. Johnson, and Carol A. Kauffman.
Clinical Infectious Diseases, 36 (5), 630-637 (2003)
Kim Vanstraelen et al.
Antimicrobial agents and chemotherapy, 58(11), 6782-6789 (2014-09-04)
Setting the adequate dose for voriconazole is challenging due to its variable pharmacokinetics. We investigated the impact of hypoalbuminemia (<35 g/liter) on voriconazole pharmacokinetics in adult intensive care unit (ICU) patients treated with voriconazole (20 samples in 13 patients) as
Yongxuan Hu et al.
Mycopathologia, 179(1-2), 103-109 (2014-11-05)
Chromoblastomycosis, a chronic fungal infection of skin and subcutaneous tissue caused by dematiaceous fungi, is associated with low cure and high relapse rates. Among all factors affecting clinical outcome, etiological agents have an important position. In southern China, Fonsecaea pedrosoi
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service